Page last updated: 2024-11-05

n-methylpiperidine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

N-methylpiperidine: RN given refers to parent cpd [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12291
CHEMBL ID281417
SCHEMBL ID1220995
MeSH IDM0164812

Synonyms (38)

Synonym
ec 210-959-9
1-methylpiperidine [un2399] [flammable liquid]
unii-617374qzn4
617374qzn4 ,
n-methylpiperidine
PDSP2_001460
626-67-5
PDSP1_001476
lk 20
einecs 210-959-9
ai3-25263
un2399
inchi=1/c6h13n/c1-7-5-3-2-4-6-7/h2-6h2,1h
1-methylpiperidine
piperidine, 1-methyl-
n-methylpiperidine, 99%
1-methylpiperidine, >=98%
CHEMBL281417
1-methyl-piperidine
M0403
n-methyl piperidine
methylpiperidine
AKOS015950624
FT-0632641
AM20100531
gtpl5522
DTXSID8060822
mfcd00006491
SCHEMBL1220995
n-methyl-piperidine
methylpiperdine
1-methyl piperidine
1-methylpiperadine
un 2399
piperidine, 1-methyl
W-104967
STR03153
Q24004759

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
"It has previously been reported that a 3-(3-(piperazin-1-yl)propyl)indole series of 5-HT1D receptor ligands have pharmacokinetic advantages over the corresponding 3-(3-(piperidin-1-yl)propyl)indole series and that the reduced pKa of the piperazines compared to the piperidines may be one possible explanation for these differences."( Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.
Beer, MS; Broughton, HB; Castro, JL; Cheng, SK; Collins, I; Goodacre, SC; Heald, A; Locker, KL; MacLeod, AM; Morrison, D; Moyes, CR; O'Connor, D; Pike, A; Rowley, M; Russell, MG; Sohal, B; Stanton, JA; Thomas, S; van Niel, MB; Verrier, H; Watt, AP, 1999
)
0.3

Bioavailability

ExcerptReferenceRelevance
" The incorporation of fluorine was found to significantly reduce the pKa of the compounds, and this reduction of basicity was shown to have a dramatic, beneficial influence on oral absorption, although the effect on oral bioavailability could not always be accurately predicted."( Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.
Beer, MS; Broughton, HB; Castro, JL; Cheng, SK; Collins, I; Goodacre, SC; Heald, A; Locker, KL; MacLeod, AM; Morrison, D; Moyes, CR; O'Connor, D; Pike, A; Rowley, M; Russell, MG; Sohal, B; Stanton, JA; Thomas, S; van Niel, MB; Verrier, H; Watt, AP, 1999
)
0.3
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID781327pKa (acid-base dissociation constant) as determined by Morgenthaler ref: ChemMedChem 20072014Pharmaceutical research, Apr, Volume: 31, Issue:4
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
AID30520Compounds was evaluate for their ability to enhance (+/-)-[3H]nicotine binding at a dose range 10 E -10 - 10 E -5 M was reported1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30389Ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 21985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID230575Relative protonation energy of the compound1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.
AID30378Maximum percent of inhibition of binding was determined1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID637270Dissociation constant, pKa of the compound2012Bioorganic & medicinal chemistry letters, Jan-01, Volume: 22, Issue:1
Design, synthesis and antitumor activity of 4-aminoquinazoline derivatives targeting VEGFR-2 tyrosine kinase.
AID30377Maximum percent of enhancement of binding.1985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID30381Compound was evaluated for ability to enhance the binding of (+/-)-[3H]nicotine to the rat brain P2 fraction at binding site 1; 10e-10-10e-51985Journal of medicinal chemistry, Sep, Volume: 28, Issue:9
Structure-activity relationships of some pyridine, piperidine, and pyrrolidine analogues for enhancing and inhibiting the binding of (+/-)-[3H]nicotine to the rat brain P2 preparation.
AID25875The compound was evaluated for the pKa units relative to N-methyl-piperazine.1999Journal of medicinal chemistry, Jun-17, Volume: 42, Issue:12
Fluorination of 3-(3-(piperidin-1-yl)propyl)indoles and 3-(3-(piperazin-1-yl)propyl)indoles gives selective human 5-HT1D receptor ligands with improved pharmacokinetic profiles.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (37.50)18.7374
1990's2 (12.50)18.2507
2000's3 (18.75)29.6817
2010's5 (31.25)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 42.99

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index42.99 (24.57)
Research Supply Index2.89 (2.92)
Research Growth Index4.56 (4.65)
Search Engine Demand Index59.70 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (42.99)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other17 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]